newsfilter
← Earnings
Earnings Releases·

KALA BIO — Third Quarter 2026 Earnings Summary

  • Reported a net loss of approximately $0.8 million for Q3 2026, a 90% reduction year-over-year from $7.6 million in Q3 2025; nine-month net loss narrowed to $4.0 million from $27.7 million in the prior year period.
  • Maintained a debt-free balance sheet with $7.0 million in cash, cash equivalents, and short-term investments as of September 30, 2026.
  • Advancing a dual strategy combining a proprietary biologics pipeline (including FDA-designated candidates) with a scalable AI platform-as-a-service business via the exclusive Researgency license and agentic transformation initiatives.
  • Preliminary results remain subject to financial close and independent audit; the formal Form 10-Q is expected to be filed with the SEC around November 16, 2026.
Company
KALA BIO INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic